CTX 471
Alternative Names: CTX-471Latest Information Update: 20 Aug 2024
At a glance
- Originator Adimab
- Developer Compass Therapeutics; Merck & Co
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 12 Aug 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 31 May 2024 Updated efficacy and adverse event data from phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology 2024 (ASCO 2024) .